MAM
BMRN icon

Marquette Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Marquette Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$916 Buy
+16
New +$876 ﹤0.01% 741
2025
Q4 		– Sell
-54
Closed -$2.92K – 725
2025
Q3 		$2.92K Buy
+54
New +$3.09K ﹤0.01% 436

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
AIM
ARGA Investment Management Stamford, Connecticut $3.92B AUM 35.93% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Marquette Asset Management's BMRN Position: Q2 2026 in Review

Marquette Asset Management opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 16 shares worth $916. The stake represents ﹤0.01% of the portfolio and ranks #741 among its holdings. This is a return to the name: Marquette Asset Management previously reported a position in BMRN as recently as Q3 2025.

Marquette Asset Management first reported a position in BMRN in Q3 2025 and has held it in 2 quarters since. The position peaked at $2.92K in Q3 2025. 257 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Marquette Asset Management held 16 shares of BioMarin Pharmaceuticals worth $916 as of Q2 2026.
  • BioMarin Pharmaceuticals was a new Marquette Asset Management position in Q2 2026.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Marquette Asset Management's portfolio in Q2 2026, its #741 holding.
  • Marquette Asset Management first reported a position in BioMarin Pharmaceuticals in Q3 2025 and has held it in 2 quarters since.
  • Marquette Asset Management's BioMarin Pharmaceuticals position peaked at $2.92K in Q3 2025.
  • 257 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Marquette Asset Management's 13F filing for Q2 2026, filed 9 Jul 2026.